Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26167663 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yasmin da Silva-Santos und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular and Molecular Immunopathology of Malaria, Department of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Science…. Hauptthemen laut MEDLINE: Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Cytokines, COVID-19 Drug Treatment. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Fundação Oswaldo Cruz, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
The regulation of angiotensin-converting enzyme 2 (ACE2) expression by medications such as ACE inhibitors (ACEis) and angiotensin receptor blockers (ARBs) has raised critical questions regarding their potential benefits and risks during COVID-19. ACE2, a regulator of blood pressure through the renin–angiotensin system (RAS), is the primary receptor for SARS-CoV-2. ACEis and ARBs can modulate ACE2 expression, potentially exacerbating viral load. However, the risks of higher viral load could be mitigated by favorable anti-inflammatory responses associated with ACEi and ARB use, highlighting the complexity of their impact on viral replication and disease outcomes. This study investigates the effects of sustained Losartan monotherapy (ARB) and combination Losartan + Lisinopril (ARB + ACEi) on viral replication, inflammation, lung function, and clinical measures of disease severity in a murine model of severe COVID-19 involving humanized ACE2 transgenic mice infected with SARS-CoV-2 Wuhan strain. Both ARB and ARB + ACEi treatments led to increased ACE2 expression in the lungs and higher viral load post-infection. Despite this, the ARB + ACEi combination improved clinical scores, reduced weight loss and inflammatory cytokine levels, and preserved lung function, though it did not improve survival. Overall, the results of these controlled experiments provide insight into the complex dynamics of ACEi and ARB use in COVID-19; while these drugs induce expression of the ACE2 receptor and increase viral load, they provide compensatory modulation of the inflammatory response that appears to diminish severity of the infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Cellular and Molecular Immunopathology of Malaria, Department of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo 05508-000, Brazil.
- Laboratory of Malaria Research, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil.
- Immunology Laboratory, Heart Institute, Faculty of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.
- Laboratory of Clinical and Molecular Virology, Institute of Biomedical Sciences, Department of Microbiology, University of São Paulo, São Paulo 05508-000, Brazil.
- Laboratory of Experimental Immunoparasitology, Institute of Biomedical Sciences, Department of Parasitology, University of São Paulo, São Paulo 05508-000, Brazil.
- Hospital Israelita Albert Einstein, São Paulo 05652-900, Brazil.
ORCID-Profile: Marcela Santiago Pacheco de Azevedo, Maria Laura Goussain Darido, Edson Luiz Durigon, Hans Christian Ackerman, Claudio Romero Farias Marinho, Leonardo José de Moura Carvalho, Sabrina Epiphanio
Förderung
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Fundação Oswaldo Cruz
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- National Council for Scientific and Technological Development
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior
- NIAID/NIH
- São Paulo Research Foundation-FAPESP
- National Council for Scientific and Technological Development-CNPq
Zitieren
APA
da Silva-Santos, Y., Pagni, R. L., Gamon, T. H. M., de Azevedo, M. S. P., Darido, M. L. G., de Oliveira, D. B. L., Durigon, E. L., Luvizotto, M. C. R., Ackerman, H. C., Marinho, C. R. F., Carvalho, L. J. M., & Epiphanio, S. (2025). Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26167663
Vancouver
da Silva-Santos Y, Pagni RL, Gamon THM, de Azevedo MSP, Darido MLG, de Oliveira DBL, et al. Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26167663
BibTeX
@article{daSilvaSantos2025,
author = {da Silva-Santos, Yasmin and Pagni, Roberta Liberato and Gamon, Thais Helena Martins and de Azevedo, Marcela Santiago Pacheco and Darido, Maria Laura Goussain and de Oliveira, Danielle Bruna Leal and Durigon, Edson Luiz and Luvizotto, Maria Cecília Rui and Ackerman, Hans Christian and Marinho, Claudio Romero Farias and Carvalho, Leonardo José de Moura and Epiphanio, Sabrina},
title = {Angiotensin-Converting Enzyme Inhibition and/or Angiotensin Receptor Blockade Modulate Cytokine Profiles and Improve Clinical Outcomes in Experimental COVID-19 Infection},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26167663}
}
EUVIMED